- Academic Editor
Background: We conducted this study to investigate adverse pregnancy
outcomes of hepatitis B virus infection coexistng with intrahepatic cholestasis
in pregnant women, along with identifying associated risk factors.
Methods: We retrospectively collected study data from Beijing Youan
Hospital in China spanning January 2014 to December 2021. The study included 220
patients, divided into two groups: Group I consisted of 110 patients with
hepatitis B virus infection and intrahepatic cholestasis during pregnancy, while
Group II comprised 110 patients with hepatitis B virus infection alone. Maternal
demographics, laboratory values, obstetric complications, and adverse pregnancy
outcomes were collected and analyzed between Groups I and II. To investigate the
features of hepatitis B virus infection with intrahepatic
cholestasis in pregnancy patients further, we also evaluated risk factors of
adverse pregnancy outcomes in Group I. Results: Adverse pregnancy
outcomes, including preterm birth (
Chronic infection with hepatitis B virus (HBV) is a public health problem in many countries. Chronic HBV infection in pregnant patients can result in virus transmission to the neonate during delivery. Accordingly, most studies have focused on mother-to-child HBV transmission, which remains the primary pathway of HBV infection [1, 2, 3]. Data about outcomes of HBV infection in pregnancy are limited, and only a few studies have reported that HBV infection may increase the occurrence of maternal complications such as miscarriage and gestational diabetes mellitus (GDM) [4, 5, 6]. Administering telbivudine during the second or third trimester of pregnancy to mothers with high viral loads is effective in reducing perinatal transmission. Women with HBV had an increased risk for preterm birth. Individuals with both HBV and hepatitis C virus co-infection had an increased risk for antepartum haemorrhage. Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease in pregnancy and is characterized by pruritus, elevated total serum bile acids (TBAs), and elevated liver enzymes. Many studies showed that ICP is associated with an increased risk of preterm birth, meconium-stained amniotic fluid (MSAF), asphyxia, or respiratory distress syndrome (RDS) [7, 8]. Recently, GDM and pre-eclampsia were reported to be associated with ICP [9, 10, 11]. The down-regulation of inducible nitric oxide synthase and up-regulation of neuropeptide Y in ICP may play a significant role in poor fetoplacental vascular perfusion and adverse pregnancy outcomes [12]. ICP may increase the incidence of shorter gestational days and non-vaginal delivery methods such as cesarean section but reduce the incidence of premature rupture of membranes and fetal macrosomia [13]. We found that elevated TBAs occurred in some pregnant HBV patients, but there have been no systematic studies involving sucah patients. Severe cholestasis is associated with neonatal morbidity which antenatal testing may not predict [14]. Therefore, our study aimed to investigate adverse pregnancy outcomes (APOs) in patients with both HBV and ICP (HBCP), as well as identify associated risk factors these APOs in HBCP patients.
Our study data were collected retrospectively between January 2014 and December
2021 from Beijing Youan Hospital, a liver disease general hospital that
specializes in treating hepatopathy in China. All patients in our study were
managed by liver specialists and experts in fetal-maternal medicine. Chronic HBV
infection was indicated by positive serum hepatitis B surface antigen (HBsAg)
status for more than 6 months and persistently normal levels of alanine
aminotransferase (ALT; 7–40 U/L) and aspartate aminotransferase (AST; 13–35
U/L) before pregnancy, with normal TBAs (
All enrolled participants also fulfilled the following criteria: (1) having complete pregnancy data; (2) absence of preexisting chronic diseases, including hypertension, diabetes mellitus, and heart, kidney, hematologic and autoimmune diseases; (3) exclusion of other infectious diseases such as hepatitis C virus infection, human immunodeficiency virus or active syphilis; cytomegalovirus, herpes simplex virus, immunoglobulin M antibodies against toxoplasma, or rubella virus; (4) no evidence of other liver diseases such as autoimmune liver diseases, nonalcoholic fatty liver diseases or gallstones, or alcoholic liver diseases by history, trans-abdominal ultrasound or liver function tests; (5) not pregnant with twins or other multiples; and (6) no miscarriage before 12 weeks.
A total of 220 patients, including 110 HBCP patients (Group I) and 110 HBV patients (Group II), were enrolled in the study. Among Groups I and II, there were 70 patients who accepted antiviral treatment during pregnancy and 40 patients who did not take antivirals separately. All patients were followed up until 6 weeks after giving birth or termination of pregnancy. In Group I, all patients received treatment with ursodeoxycholic acid (UDCA; 10–15 mg/kg per day) upon diagnosis. Serum TBAs, ALT, AST, total bilirubin (TBIL; normal range, 5–20 µmol/L), unconjugated bilirubin (DBIL; 1.7–10 µmol/L), gamma-glutamyl transpeptidase (GGT; 7–45 U/L), and alkaline phosphatase (ALP; 35–100 U/L) levels were analyzed weekly. Fetal monitoring by an ultrasound examination and Echo-Doppler detection was conducted weekly. Maternal demographics, laboratory values, obstetric complications, and APOs were collected and analyzed between Groups I and II. To investigate the features of HBCP patients further, we also evaluated risk factors of APOs in Group I.
Obesity was defined as a body mass index (BMI) of
Statistical analysis was performed using SPSS version 20 (IBM, Armonk, NY, USA).
Results are presented as the median or mean
A comparison between the demographic and clinical data in patients with HBCP and
HBV is presented in Table 1. The rate of demographic characteristics such as
unigravida, age, in vitro fertilization and embryo transfer (IVF-ET)
management, obesity, and live birth were similar in both groups (p
Characteristics | Group I (N = 110) | Group II (N = 110) | p | |||
n | % | n | % | |||
Unigravida | 78 | 70.91 | 65 | 59.09 | 0.066 | |
Multigravida | 32 | 29.09 | 45 | 40.91 | 0.066 | |
Age (Y) | 29.14 |
30.11 |
||||
IVF-ET | 5 | 4.54 | 3 | 2.73 | 0.719 | |
Obesity | 8 | 7.27 | 5 | 4.54 | 0.391 | |
Live birth | 105 | 95.45 | 109 | 99.09 | 0.214 | |
by vagina |
42 | 38.18 | 66 | 60.00 | 0.015 | |
by cesarean section |
63 | 57.27 | 43 | 39.09 | 0.007 |
Obesity: Body Mass Index (BMI)
IVF-ET, in vitro fertilization and embryo transfer; Y, years.
p: Group I vs. Group II.
Table 2 describes the laboratory values in the study. There was no difference
between the groups for ALP (p
Serum parameters, mean |
Group I | Group II | p |
TBA (µmol/L) |
53.89 |
6.23 |
|
ALT (U/L) |
92.48 |
22.19 |
|
AST (U/L) |
76.14 |
23.21 |
|
TBIL (µmol/L) |
14.16 |
9.66 |
0.009 |
DBIL (µmol/L) |
6.05 |
3.01 |
0.007 |
GGT (U/L) |
25.64 |
12.87 |
|
ALP (U/L) | 98.74 |
91.97 |
0.325 |
SD, standard deviation; TBA, total serum bile acids (
p: Group I vs. Group II.
Obstetric complications for all patients are summarized in Table 3. Six patients
were diagnosed with PIH (5.45%), including one with gestational hypertension
(0.91%) and five with preeclampsia (4.55%) in Group I, which was not different
compared with Group II (p
Obstetric complications | Group I (N = 110) | Group II (N = 110) | p | |||
n | % | n | % | |||
PIH | 6 | 5.45 | 3 | 2.73 | 0.496 | |
Gestational hypertension | 1 | 0.91 | 2 | 1.82 | ||
Preeclampsia | 5 | 4.55 | 1 | 0.91 | 0.214 | |
PROM | 15 | 13.64 | 15 | 13.64 | ||
GDM | 22 | 20.00 | 13 | 11.82 | 0.097 | |
Premature birth | ||||||
5 | 4.55 | 0 | 0 | |||
8 | 7.27 | 2 | 1.82 | 0.052 | ||
26 | 23.64 | 2 | 1.82 | |||
Postpartum hemorrhage |
12 | 10.91 | 3 | 2.73 | 0.016 | |
Placental abruption | 2 | 1.82 | 1 | 0.91 |
PIH, pregnancy-induced hypertension; PROM, premature rupture of membrane; GDM, gestational diabetes mellitus; w, week.
p: Group I vs. Group II.
The APOs for the two groups are reported in Table 4. Overall, almost all APOs in
our study occurred in Group I. Adverse maternal pregnancy outcomes including
preterm birth (
Adverse pregnancy outcomes | Group I (N = 110) | Group II (N = 110) | p | |||
n | % | n | % | |||
Maternal | ||||||
Premature birth |
||||||
26 | 23.64 | 2 | 1.82 | |||
Postpartum hemorrhage |
12 | 10.91 | 3 | 2.73 | 0.016 | |
Neonatal | ||||||
MSAF |
33 | 30.00 | 12 | 10.91 | ||
Fetal loss | 5 | 4.55 | 1 | 0.91 | 0.214 | |
Late abortion | 1 | 0.91 | 0 | 0 | ||
Intrauterine death | 2 | 1.82 | 1 | 0.91 | ||
Induced labor | 1 | 0.91 | 0 | 0 | ||
Perinatal mortality | 1 | 0.91 | 0 | 0 | ||
Neonatal asphyxia |
13 | 11.82 | 4 | 3.64 | 0.023 | |
Aspiration syndrome | 6 | 5.45 | 1 | 0.91 | 0.124 | |
NRDS | 5 | 4.55 | 1 | 0.91 | 0.214 | |
NICU admission |
10 | 9.09 | 2 | 1.82 | 0.018 | |
Pneumonia | 6 | 5.45 | 2 | 1.82 | 0.28 | |
Hyperbilirubinemia | 3 | 2.73 | 4 | 3.64 | ||
Hypoglycemia | 3 | 2.73 | 3 | 2.73 | ||
Encephalopathy | 2 | 1.82 | 0 | 0 | ||
Birth defects | 7 | 6.36 | 4 | 3.64 | 0.353 | |
SGA |
17 | 15.45 | 3 | 2.73 | 0.001 |
NICU admission, neonate intensive care unit admission; NRDS, neonatal respiratory distress syndrome; MSAF, meconium-stained amniotic fluid; SGA, small for gestational age.
p: Group I vs. Group II.
To evaluate the risk factors statistically, we extracted the baseline data at
the time of conception, including demographic data, laboratory values, and
obstetric complications between Groups I and II. Single factor analysis showed
statistically significant differences between the two groups for the following
variables: TBAs, ALT, AST, TBIL, DBIL, and GGT. Accordingly, these variables were
further analyzed using a multivariable logistic regression model to evaluate risk
factors for the following six APOs: preterm birth (
Maternal risk factor | Adverse Pregnant Outcomes | ||
Odds ratio (OR) | 95% CI | p value | |
TBA |
1.013 | 1.001–1.026 | 0.038 |
ALT | 1.013 | 0.998–1.028 | 0.099 |
AST | 0.981 | 0.961–1.000 | 0.053 |
TBIL | 1.017 | 0.933–1.109 | 0.695 |
DBIL | 1.028 | 0.932–1.135 | 0.577 |
GGT | 1.008 | 0.987–1.029 | 0.458 |
95% CI, 95% confidence interval.
p: Group I vs. Group II.
Cholestasis, classified as either intrahepatic or extrahepatic, is a barrier to bile formation or flow. Inhibiting or restricting bile flow leads to high TBA levels. Extrahepatic cholestasis is usually caused by biliary obstruction such as stones, tumors, and cysts; patients with this condition were excluded from our study [15]. Intrahepatic cholestasis may be caused by hepatocyte dysfunction or obstructive lesions at the end of the intrahepatic bile duct [16]. Our study focused on the effect of intrahepatic cholestasis on APOs resulting from HBV during pregnancy. HBV causes chronic inflammatory liver diseases, which can lead to hepatocellular damage and intrahepatic cholestasis. Intrahepatic cholestasis also aggravates liver damage. Additionally, changes in hormone levels during pregnancy can increase the burden on the liver and aggravate liver disease [17, 18]. However, the mechanism of intrahepatic cholestasis in HBV patients remains unclear.
ICP is a pregnancy-associated liver disease that is characterized by elevated TBAs. Numerous studies have reported that ICP is associated with a poor perinatal outcomes such as preterm delivery, MSAF, and fetal distress [19, 20]. Only one study exclusively explored pregnancy outcomes, primarily focusing on fetal outcomes witjin the context of HBCP patients [21]. Thus, we conducted our study to estimate the APOs for HBCP patients and to determine the risk factors for APOs in HBCP patients. To the best of our knowledge, our study is the largest and the most systematic study about HBCP patients, and is the first to estimate risk factors for APOs in HBCP patients.
We compared laboratory values between HBCP and HBV patients and found that,
except for ALP, all biochemical indices in HBCP patients were higher than those
in HBV patients (p
For maternal obstetric complications, preterm birth (
The percentage of adverse maternal pregnancy outcomes such as preterm birth and
postpartum hemorrhage, and neonatal pregnancy outcomes such as MSAF, neonatal
asphyxia, NICU admission, and SGA, were higher in HBCP patients compared with HBV
patients (p
There was higher incidence of APOs such as premature birth, postpartum
hemorrhage, MSAF, neonatal asphyxia, NICU admission, and SGA in HBCP patients. To
administer treatment in a timely manner and to improve pregnancy outcomes, our
study also assessed risk factors for APOs, including TBA level, ALT, AST, TBIL,
DBIL, and GGT, using a multivariable logistic regression analysis. We found that
only TBAs were an independent risk factor for these APOs. Many studies on ICP
patients have reported a high TBA level (
The main limitation was the retrospective nature of our data collection and our single-center study, which limits the generalizability of our results. Second, we found that HBCP patients had a higher preterm birth rate. However, we did not divide preterm births into iatrogenic and spontaneous preterm births because we also found a higher cesarean section delivery rate in HBCP patients. Additionally, all our HBCP patients received UDCA treatment, which may affect the objectivity of the results. Finally, our sample size was relatively small, and we did not group TBAs according to the degree of their increase, and APOs associated with different degrees of TBA increase requires further analysis. The small sample size of our treatment group limited the ability to detect statistically significant differences, necessitating further research and follow-up in the future.
HBV, hepatitis B virus; GDM, gestational diabetes mellitus; ICP, intrahepatic cholestasis of pregnancy; TBAs, otal serum bile acids; MSAF, meconium-stained amniotic fluid; RDS, respiratory distress syndrome; APOs, adverse pregnancy outcomes; HBCP, hepatitis B virus with intrahepatic cholestasis of pregnancy; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; UDCA, ursodeoxycholic acid; TBIL, total bilirubin; DBIL, unconjugated bilirubin; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; BMI, body mass index; PIH, pregnancy-induced hypertension; PROM, premature rupture of membranes; NRDS, neonatal respiratory distress syndrome; NICU, neonate intensive care unit; SGA, small for gestational age; SD, standard deviation; ORs, odds ratios; IVF-ET, in vitro fertilization and embryo transfer.
The datasets used during the current study are available from the corresponding author on reasonable request.
YZ designed the research study. HW and ZZ analyzed the data. YZ, HW and ZZ revised the manuscript critically for important intellectual content. CZ had substantial contributions to the design of the work and wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
The study was approved by Beijing Youan Hospital, Capital Medical University Human Research Protection Program (2015-32). Informed consent was obtained from the patient.
We thank Hongliang Zhang for his assistance in conducting this study.
This research received no external funding.
The authors declare no conflict of interest.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.